fundvisualizer.com

Global X China Biotech Innovation ETFCHB

Performance (before sales charge)

As of 02/28/2023

All information is historical and not indicative of future results. Current performance may be lower or higher than the quoted past performance, which cannot guarantee results. Share price, principal value, and return will vary, and you may have a gain or a loss when you sell your shares. Performance assumes reinvestment of distributions and does not account for taxes. After-sales-charge returns reflect the maximum sales charge applicable to the fund. Performance may not reflect any expense limitation or subsidies currently in effect. Short-term trading fees may apply. To obtain the most recent month-end performance, visit Morningstar.com.

Asset allocation

As of 02/28/2023
Stock
4.55%
Non-U.S. Stock
95.44%
Bond
0.00%
Non-U.S. Bond
0.00%
Preferred
0.00%
Convertible
0.00%
Cash
0.01%
Other
0.00%

Due to rounding, percentages may not equal 100%.

Sectors

As of 02/28/2023

Basic materials

0.00%

Consumer cyclical

0.00%

Financial services

0.00%

Real estate

0.00%

Consumer defensive

0.00%

Health care

99.99%

Utilities

0.00%

Communication services

0.00%

Energy

0.00%

Industrials

0.00%

Technology

0.00%

Top 10 holdings

As of 02/28/2023

WuXi Biologics (Cayman) Inc
10.55%
United States Treasury Bills 0%
9.49%
Cash
9.48%
Changchun High and New Technology Industry Group Inc Class A
8.40%
Walvax Biotechnology Co Ltd Class A
7.74%
CSPC Pharmaceutical Group Ltd
7.46%
Chongqing Zhifei Biological Products Co Ltd Class A
7.40%
Zai Lab Ltd ADR Repr 1 Shs
5.68%
Sichuan Kelun Pharmaceutical Co Ltd Class A
5.16%
Shanghai RAAS Blood Products Co Ltd Class A
5.11%
Fund assets

$2.63 Million

Share class

--

Morningstar category

China Region

Expense ratio

0.65%

Investment objective

Specialty - Technology

Documents